Drugs / Trastuzumab and Hyaluronidase-oysk
Trastuzumab and Hyaluronidase-oysk
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06100874 | Nov 2023 → Feb 2026 overdue | HER2 positive breast carcinoma, female breast carcinoma | Adrienne G. Waks | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trastuzumab and Hyaluronidase-oysk | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06100874 ↗ |
| Modality | Monoclonal antibody | “a type of recombinant monoclonal antibody” NCT06100874 ↗ |
| Route | Subcutaneous | “via subcutaneous injection per protocol” NCT06100874 ↗ |